News

Seelos Therapeutics will begin animal studies to test a gene therapy approach to deliver its investigational candidate SLS-007 for Parkinson’s disease. SLS-007, originally developed by scientists at the University of California, Los Angeles, is intended to lessen the aggregation, or clumping, of alpha-synuclein protein —…

Bone marrow stem cells treated with fasudil and administered via the nose (intranasal) to mice in a model of Parkinson’s disease led to evidence of better motor abilities and a reduced of dopaminergic neurons,  a recent study from China reports. These results suggest that fasudil’s use and intranasal delivery…

The U.S. Food and Drug Administration (FDA) has responded to Affiris‘  pre-investigational new drug (IND) submission regarding a planned Phase 2 clinical trial of the potential Parkinson’s vaccine Affitope (PD01A). After reviewing previous preclinical and clinical data, the FDA answered questions posed by the company…

People who develop Parkinson’s disease before the age of 50 may have been born with the defective brain cells responsible for causing the illness, a study suggests. These results also reveal that a medicine, which is already approved by the U.S. Food and Drug Administration (FDA) for treating…

People who live less than 50 meters (about 54 yards) from major roads or 150 meters (164 yards) from a highway have a higher risk of developing Parkinson’s disease or other neurodegenerative disorders, according to a Canadian study. Meanwhile, green spaces such as parks seem to offer protection and lower…

The U.S. Food and Drug Administration (FDA) has expanded Abbott’s Infinity Deep Brain Stimulation (DBS) system approval to target a brain region critical for motor functions — the globus pallidus — as a way to lessen motor symptoms in Parkinson’s disease patients who still show impairments after medication.

A new small molecule called synucleozid can prevent cells from producing the Parkinson’s-associated protein alpha-synuclein by inhibiting its translation from RNA, a study shows. The study, “Translation of the intrinsically disordered protein α-synuclein is inhibited by a small molecule targeting its structured mRNA,” was published in…

Two key types of brain nerves cells affected by Parkinson’s disease — cholinergic neurons and dopaminergic neurons — communicate and interact via signaling systems, researchers were able to “see” using a new imaging approach. This beneficial neuron-to-neuron interaction, confirmed through the novel approach in a rat model of the…

The Parkinson’s Foundation has established a first Parkinson’s Nurse Fellowship program in the U.S., offering one year of training and support to working nurses who want to specialize in treating people with this progressive disease. Applications are being accepted through Feb. 20 for the fellowship, worth up to…

Blood levels of valosin-containing protein (VCP) — an enzyme involved in protein degradation — may be used as a biomarker of preclinical and early clinical stages of Parkinson’s disease (PD), a study suggests. Reduced levels of VCP in the blood were found in both animal models of the…